Concepts (247)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Papillomavirus Infections | 36 | 2025 | 288 | 8.860 |
Why?
|
| Oropharyngeal Neoplasms | 34 | 2025 | 163 | 8.690 |
Why?
|
| Carcinoma, Squamous Cell | 30 | 2024 | 662 | 3.370 |
Why?
|
| Human papillomavirus 16 | 18 | 2025 | 48 | 3.290 |
Why?
|
| Papillomaviridae | 18 | 2023 | 138 | 2.530 |
Why?
|
| Alphapapillomavirus | 5 | 2022 | 30 | 2.010 |
Why?
|
| DNA, Viral | 6 | 2025 | 480 | 1.740 |
Why?
|
| Head and Neck Neoplasms | 17 | 2024 | 499 | 1.720 |
Why?
|
| Antibodies, Viral | 6 | 2025 | 1153 | 1.500 |
Why?
|
| Oncogene Proteins, Viral | 4 | 2025 | 57 | 1.320 |
Why?
|
| Papillomavirus Vaccines | 5 | 2022 | 94 | 1.240 |
Why?
|
| Anus Neoplasms | 3 | 2022 | 38 | 1.120 |
Why?
|
| Uterine Cervical Neoplasms | 5 | 2022 | 237 | 1.090 |
Why?
|
| Smoking | 11 | 2023 | 1044 | 0.930 |
Why?
|
| Circulating Tumor DNA | 1 | 2025 | 33 | 0.930 |
Why?
|
| Sexual Behavior | 4 | 2018 | 247 | 0.860 |
Why?
|
| Mouth Diseases | 1 | 2023 | 11 | 0.850 |
Why?
|
| Early Detection of Cancer | 5 | 2025 | 356 | 0.770 |
Why?
|
| Alcohol Drinking | 6 | 2016 | 344 | 0.740 |
Why?
|
| Penile Neoplasms | 1 | 2021 | 33 | 0.730 |
Why?
|
| Middle Aged | 46 | 2025 | 26756 | 0.720 |
Why?
|
| Mouth Neoplasms | 7 | 2023 | 84 | 0.720 |
Why?
|
| Biomarkers, Tumor | 4 | 2025 | 1473 | 0.670 |
Why?
|
| Health Care Costs | 3 | 2020 | 371 | 0.660 |
Why?
|
| Condylomata Acuminata | 1 | 2018 | 15 | 0.620 |
Why?
|
| Case-Control Studies | 17 | 2023 | 3290 | 0.600 |
Why?
|
| Microbiota | 1 | 2023 | 391 | 0.590 |
Why?
|
| Male | 49 | 2025 | 61355 | 0.590 |
Why?
|
| Mouth | 1 | 2018 | 61 | 0.570 |
Why?
|
| Cancer Survivors | 1 | 2020 | 206 | 0.570 |
Why?
|
| Humans | 65 | 2025 | 124905 | 0.470 |
Why?
|
| Prognosis | 13 | 2024 | 4615 | 0.450 |
Why?
|
| Vaccination | 2 | 2018 | 955 | 0.450 |
Why?
|
| Neoplasm Staging | 8 | 2016 | 1228 | 0.440 |
Why?
|
| Female | 49 | 2024 | 66624 | 0.440 |
Why?
|
| Aged | 30 | 2024 | 19712 | 0.410 |
Why?
|
| Laryngeal Neoplasms | 3 | 2020 | 80 | 0.370 |
Why?
|
| Prospective Studies | 7 | 2024 | 6143 | 0.370 |
Why?
|
| Prevalence | 8 | 2023 | 2451 | 0.350 |
Why?
|
| Sex Distribution | 5 | 2019 | 301 | 0.330 |
Why?
|
| Age Distribution | 5 | 2018 | 415 | 0.330 |
Why?
|
| Risk Factors | 18 | 2023 | 10281 | 0.320 |
Why?
|
| Texas | 8 | 2021 | 3592 | 0.300 |
Why?
|
| Insurance, Health | 2 | 2019 | 138 | 0.290 |
Why?
|
| Medicaid | 2 | 2019 | 242 | 0.270 |
Why?
|
| Reference Values | 5 | 2017 | 713 | 0.260 |
Why?
|
| Incidence | 9 | 2020 | 3146 | 0.260 |
Why?
|
| In Situ Hybridization | 2 | 2017 | 470 | 0.250 |
Why?
|
| Logistic Models | 4 | 2017 | 1811 | 0.250 |
Why?
|
| Adult | 23 | 2024 | 29498 | 0.240 |
Why?
|
| Age Factors | 3 | 2020 | 2821 | 0.230 |
Why?
|
| Cost-Benefit Analysis | 3 | 2020 | 512 | 0.230 |
Why?
|
| Polymerase Chain Reaction | 5 | 2019 | 1588 | 0.230 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 1328 | 0.230 |
Why?
|
| Cohort Studies | 7 | 2017 | 4788 | 0.230 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2022 | 3151 | 0.220 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2018 | 129 | 0.220 |
Why?
|
| Smokers | 2 | 2020 | 39 | 0.220 |
Why?
|
| Retrospective Studies | 10 | 2022 | 16309 | 0.220 |
Why?
|
| Follow-Up Studies | 7 | 2018 | 5158 | 0.220 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2020 | 1030 | 0.210 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2017 | 824 | 0.210 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2022 | 2630 | 0.210 |
Why?
|
| Anus Diseases | 1 | 2022 | 12 | 0.210 |
Why?
|
| Vulvar Neoplasms | 1 | 2022 | 18 | 0.200 |
Why?
|
| Cotinine | 3 | 2008 | 23 | 0.200 |
Why?
|
| Proportional Hazards Models | 5 | 2024 | 1352 | 0.200 |
Why?
|
| Carcinoma in Situ | 1 | 2022 | 71 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 1135 | 0.190 |
Why?
|
| Polymorphism, Genetic | 5 | 2016 | 810 | 0.190 |
Why?
|
| Mouthwashes | 1 | 2021 | 10 | 0.190 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 370 | 0.190 |
Why?
|
| Neoplasms, Second Primary | 2 | 2013 | 154 | 0.180 |
Why?
|
| Pharyngeal Neoplasms | 3 | 2008 | 26 | 0.180 |
Why?
|
| Cross-Sectional Studies | 4 | 2023 | 3449 | 0.180 |
Why?
|
| Tongue Neoplasms | 1 | 2020 | 19 | 0.180 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2020 | 15 | 0.170 |
Why?
|
| Radiotherapy Dosage | 1 | 2020 | 187 | 0.170 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2020 | 70 | 0.170 |
Why?
|
| Sex Factors | 3 | 2018 | 1285 | 0.170 |
Why?
|
| MicroRNAs | 2 | 2018 | 840 | 0.170 |
Why?
|
| Smoking Cessation | 2 | 2020 | 197 | 0.170 |
Why?
|
| Tobacco Products | 1 | 2020 | 61 | 0.170 |
Why?
|
| Direct Service Costs | 1 | 2019 | 8 | 0.160 |
Why?
|
| Bayes Theorem | 1 | 2020 | 283 | 0.160 |
Why?
|
| United States | 7 | 2020 | 10884 | 0.160 |
Why?
|
| Squamous Intraepithelial Lesions of the Cervix | 1 | 2019 | 2 | 0.160 |
Why?
|
| Capsid Proteins | 2 | 2018 | 183 | 0.160 |
Why?
|
| Oropharynx | 2 | 2013 | 34 | 0.160 |
Why?
|
| DNA-Binding Proteins | 4 | 2015 | 2060 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2019 | 100 | 0.160 |
Why?
|
| Anal Canal | 1 | 2019 | 80 | 0.150 |
Why?
|
| Academic Medical Centers | 2 | 2017 | 307 | 0.150 |
Why?
|
| Genital Neoplasms, Female | 1 | 2019 | 47 | 0.150 |
Why?
|
| Cause of Death | 1 | 2020 | 472 | 0.150 |
Why?
|
| Risk Assessment | 5 | 2017 | 3439 | 0.150 |
Why?
|
| Repressor Proteins | 1 | 2003 | 820 | 0.150 |
Why?
|
| Mass Screening | 2 | 2022 | 783 | 0.150 |
Why?
|
| Odds Ratio | 4 | 2016 | 1252 | 0.150 |
Why?
|
| Body Mass Index | 1 | 2024 | 1570 | 0.140 |
Why?
|
| Survival Analysis | 3 | 2024 | 1499 | 0.140 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 1997 | 19 | 0.140 |
Why?
|
| Alcohols | 1 | 1997 | 18 | 0.140 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 555 | 0.140 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1997 | 135 | 0.140 |
Why?
|
| Lymphocytes | 3 | 2016 | 407 | 0.140 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 230 | 0.140 |
Why?
|
| Linear Models | 1 | 2018 | 677 | 0.130 |
Why?
|
| Young Adult | 4 | 2020 | 9000 | 0.130 |
Why?
|
| Genes, p16 | 1 | 2016 | 13 | 0.130 |
Why?
|
| Fungal Proteins | 1 | 1997 | 134 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2019 | 271 | 0.130 |
Why?
|
| Recombinational DNA Repair | 1 | 2016 | 19 | 0.130 |
Why?
|
| Genotype | 8 | 2022 | 2557 | 0.130 |
Why?
|
| Models, Statistical | 1 | 2018 | 471 | 0.130 |
Why?
|
| DNA Repair | 3 | 2005 | 587 | 0.130 |
Why?
|
| RNA Helicases | 1 | 2015 | 63 | 0.120 |
Why?
|
| Adolescent | 5 | 2021 | 19339 | 0.120 |
Why?
|
| Cancer Care Facilities | 2 | 2016 | 30 | 0.120 |
Why?
|
| Apoptosis | 2 | 2016 | 1792 | 0.120 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 271 | 0.110 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1997 | 426 | 0.110 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2014 | 92 | 0.110 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 1691 | 0.110 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 2043 | 0.110 |
Why?
|
| Extremities | 1 | 2013 | 83 | 0.110 |
Why?
|
| Telomere Homeostasis | 1 | 2013 | 42 | 0.110 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2013 | 53 | 0.100 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2013 | 29 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2013 | 142 | 0.100 |
Why?
|
| Disease-Free Survival | 3 | 2024 | 868 | 0.100 |
Why?
|
| Survival Rate | 3 | 2024 | 2038 | 0.100 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 872 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 300 | 0.100 |
Why?
|
| Confidence Intervals | 2 | 2010 | 283 | 0.090 |
Why?
|
| Biomarkers | 1 | 2020 | 3065 | 0.090 |
Why?
|
| Demography | 1 | 2012 | 240 | 0.090 |
Why?
|
| Sarcoma | 1 | 2013 | 194 | 0.090 |
Why?
|
| Pilot Projects | 4 | 2023 | 1402 | 0.090 |
Why?
|
| Time Factors | 1 | 2020 | 6313 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2010 | 79 | 0.090 |
Why?
|
| Medical History Taking | 1 | 2010 | 108 | 0.080 |
Why?
|
| Binding Sites | 3 | 2018 | 1297 | 0.080 |
Why?
|
| Tumor Virus Infections | 1 | 2010 | 135 | 0.080 |
Why?
|
| Disease Progression | 1 | 2015 | 2052 | 0.080 |
Why?
|
| Immunoglobulin G | 3 | 2015 | 776 | 0.080 |
Why?
|
| Codon | 1 | 2008 | 97 | 0.070 |
Why?
|
| Dronabinol | 1 | 2008 | 30 | 0.070 |
Why?
|
| Seroepidemiologic Studies | 1 | 2008 | 121 | 0.070 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2008 | 51 | 0.070 |
Why?
|
| Carcinogens | 1 | 2008 | 153 | 0.070 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2008 | 76 | 0.070 |
Why?
|
| Occupational Exposure | 1 | 2008 | 129 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2020 | 12354 | 0.070 |
Why?
|
| Surgical Flaps | 1 | 2008 | 204 | 0.060 |
Why?
|
| Secondary Prevention | 2 | 2020 | 217 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 2092 | 0.060 |
Why?
|
| Gastroesophageal Reflux | 1 | 2008 | 294 | 0.060 |
Why?
|
| Gastrostomy | 1 | 2005 | 85 | 0.060 |
Why?
|
| G2 Phase | 1 | 2004 | 44 | 0.060 |
Why?
|
| Gamma Rays | 1 | 2004 | 49 | 0.060 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2004 | 55 | 0.060 |
Why?
|
| Registries | 1 | 2010 | 1423 | 0.060 |
Why?
|
| Genome-Wide Association Study | 2 | 2022 | 1683 | 0.050 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2003 | 19 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2008 | 724 | 0.050 |
Why?
|
| Lymphatic Metastasis | 2 | 2016 | 410 | 0.050 |
Why?
|
| State Medicine | 1 | 2022 | 12 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2022 | 2826 | 0.050 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 1 | 2022 | 5 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2022 | 15 | 0.050 |
Why?
|
| Endonucleases | 1 | 2002 | 54 | 0.050 |
Why?
|
| Canada | 1 | 2022 | 300 | 0.050 |
Why?
|
| Thyroid Neoplasms | 1 | 2004 | 199 | 0.050 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2022 | 116 | 0.050 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2001 | 18 | 0.050 |
Why?
|
| Nutrition Surveys | 1 | 2023 | 293 | 0.050 |
Why?
|
| Risk | 1 | 2003 | 758 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2002 | 227 | 0.050 |
Why?
|
| Vagina | 1 | 2022 | 196 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 6528 | 0.040 |
Why?
|
| Mass Vaccination | 1 | 2020 | 12 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2023 | 762 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 1425 | 0.040 |
Why?
|
| Patient Preference | 1 | 2020 | 119 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2020 | 288 | 0.040 |
Why?
|
| Genitalia, Female | 1 | 2019 | 47 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2020 | 248 | 0.040 |
Why?
|
| SEER Program | 1 | 2019 | 202 | 0.040 |
Why?
|
| DNA | 1 | 2023 | 1604 | 0.040 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2019 | 241 | 0.030 |
Why?
|
| Genetic Complementation Test | 1 | 1997 | 87 | 0.030 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2016 | 16 | 0.030 |
Why?
|
| Proteins | 1 | 2002 | 1045 | 0.030 |
Why?
|
| Glycerol | 1 | 1997 | 92 | 0.030 |
Why?
|
| Hydrolysis | 1 | 1997 | 163 | 0.030 |
Why?
|
| Camptothecin | 1 | 2016 | 76 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 1997 | 291 | 0.030 |
Why?
|
| Viral Core Proteins | 1 | 2016 | 22 | 0.030 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2015 | 9 | 0.030 |
Why?
|
| Mutagenesis | 1 | 1997 | 348 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2003 | 1931 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2002 | 1496 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2015 | 165 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 1175 | 0.030 |
Why?
|
| Helicobacter pylori | 1 | 2005 | 1321 | 0.030 |
Why?
|
| Computational Biology | 1 | 2020 | 821 | 0.030 |
Why?
|
| Helicobacter Infections | 1 | 2005 | 1264 | 0.030 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2016 | 133 | 0.030 |
Why?
|
| Kinetics | 1 | 1997 | 1325 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 804 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 2886 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 570 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2016 | 380 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 510 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2013 | 143 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 1997 | 1395 | 0.030 |
Why?
|
| Genome | 1 | 2016 | 476 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 161 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 1291 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2013 | 356 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 1249 | 0.020 |
Why?
|
| Base Sequence | 1 | 1997 | 3100 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2002 | 2609 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 1997 | 3882 | 0.020 |
Why?
|
| Cocarcinogenesis | 1 | 2010 | 23 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 1948 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 3061 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 3342 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 1092 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 2143 | 0.020 |
Why?
|
| Immunoassay | 1 | 2008 | 130 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2005 | 143 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2004 | 124 | 0.010 |
Why?
|
| Patient Selection | 1 | 2008 | 692 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 1668 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2019 | 14055 | 0.010 |
Why?
|
| Antibodies, Bacterial | 1 | 2005 | 388 | 0.010 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2002 | 21 | 0.010 |
Why?
|
| Exons | 1 | 2005 | 796 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2002 | 70 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2002 | 303 | 0.010 |
Why?
|
| Alleles | 1 | 2005 | 1619 | 0.010 |
Why?
|
| Child | 1 | 2019 | 24476 | 0.010 |
Why?
|
| Alcoholism | 1 | 2001 | 231 | 0.010 |
Why?
|
| Comorbidity | 1 | 2001 | 1533 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2005 | 3728 | 0.010 |
Why?
|